Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Selectis Health (GBCS) EBITDA Margin (2017 - 2025)

Selectis Health's EBITDA Margin history spans 14 years, with the latest figure at 4.09% for Q4 2025.

  • Quarterly results put EBITDA Margin at 4.09% for Q4 2025, down 2451.0% from a year ago — trailing twelve months through Dec 2025 was 1.14% (down 291.0% YoY), and the annual figure for FY2025 was 3.78%, down 249.0%.
  • EBITDA Margin for Q4 2025 was 4.09% at Selectis Health, down from 0.62% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 24.78% in Q1 2021 to a low of 27.84% in Q4 2023.
  • The 5-year median for EBITDA Margin is 1.86% (2024), against an average of 1.92%.
  • The sharpest move saw EBITDA Margin tumbled -3958bps in 2021, then soared 4826bps in 2024.
  • Year by year, EBITDA Margin stood at 7.02% in 2021, then crashed by -30bps to 9.15% in 2022, then plummeted by -204bps to 27.84% in 2023, then surged by 173bps to 20.42% in 2024, then tumbled by -120bps to 4.09% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 4.09%, 0.62%, and 0.84% for Q4 2025, Q3 2025, and Q2 2025 respectively.